Share
Export Citation
Analysis of serum interleukin 6 level in coronavirus disease-19 patients’ survivability
Alim A.
Gazzetta Medica Italiana Archivio Per Le Scienze Mediche
Q4Abstract
BACKGROUND: The degree of severity of COVID-19 also varies widely. Accompanying COVID-19 patient acute respiratory distress syndrome (ARDS) demonstrated that virus-induced proinflammatory cytokines including interleukin 6 (IL-6) lead to a hyperinflammatory and procoagulable state in the late stages of the disease. The aim of this study was to assess the condition of COVID-19 patients with IL-6 as a marker.METHODS: A retrospective cohort study was taken on 111 COVID-19 patients. Patients who have a history of autoimmune, cancer, trauma, burn injury, or undergoing surgery were excluded from the study. Demographic and clinical data were collected. Interleukin 6 is measured by 6 mL plasma testing with electrochemiluminescence (ECL) Cobas® e601 (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) with IL-6 Human ProQuantum Immunoassay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Baseline data were descriptively summarized, and the differences in each variable between groups were calculated using Kruskal-Wallis and Mann-Whittney Tests. Interleukin 6 associated with survivability was analyzed using Kaplan-Meier Survival Curve, and outcomes were reported with 95% confidence intervals (CI).RESULTS: Survivability at 37.65 pg/mL higher IL-6 correlates with lesser survival days. IL-6 cut-off at 53.57 pg/mL with 70.7% sensitivity and 70% specificity.CONCLUSIONS: Serum IL-6 levels have a positive correlation with mortality and could be a predictor of death in COVID-19 patients.